![]() (Read more: Eli Lilly’s Cluster Headache Candidate Succeeds in Phase III) However, a separate phase III study evaluating galcanezumab in patients with chronic cluster headache did not meet the primary endpoint. Galcanezumab is already under review in the United States for migraine prevention with a decision expected in the third quarter of the year. In another development, its migraine candidate galcanezumab met the primary endpoint in a late-stage study, evaluating it for another indication - prevention of episodic cluster headache. (Read More: Eli Lilly to Buy AurKa Pharma, Expand Cancer Pipeline) ![]() Last week, Lilly had announced an all-cash deal tobuy immuno-oncology biotech, ARMO Biosciences for $1.6 billion. ![]() This is Lilly’s second cancer acquisition in less than a week. Lilly will make an upfront payment of $110 million and acquire all shares of AurKa Pharma. Lilly’s to Buy Another Small Cancer Biotech: Lilly has agreed to buy an early-phase oncology asset, AK-01, from AurKa Pharma to expand its oncology pipeline. Recap of the Week’s Most Important Stories Zoetis ( ZTS Quick Quote ZTS - Free Report) and Lilly announced acquisition deals. Its CGRP antibody, Aimovig, also gained FDA approval for prevention of migraine. Novartis’ multiple sclerosis (“MS”) drug Gilenya gained FDA approval for use in adolescents. ![]() While AstraZeneca’s asthma drug Fasenra failed to meet the primary endpoint in a late-stage study evaluating it for an expanded indication - chronic obstructive pulmonary disease (“COPD”) Lilly’s migraine candidate galcanezumab met the same in a late-stage study, evaluating it for another indication - prevention of episodic cluster headache. This week AstraZeneca ( AZN Quick Quote AZN - Free Report), Novartis ( NVS Quick Quote NVS - Free Report) and Eli Lilly ( LLY Quick Quote LLY - Free Report) announced regulatory and pipeline updates on line extensions of their marketed drugs. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |